Drugs / p95HER2.CAR-TECH2Me
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07593820 | Apr 2026 → Jun 2030 expected | breast cancer, endometrial cancer, gastric cancer | Vall d'Hebron Institute of Oncology | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | p95HER2.CAR-TECH2Me | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07593820 ↗ |
| Modality | Cell therapy | “The p95HER2.CAR-TECH2Me product is a cellular investigational product comprising a live cell suspension of autologous CAR-T lymphocytes derived from the patient's peripheral blood.” NCT07593820 ↗ |
| Route | Intravenous | “following intravenous administration” NCT07593820 ↗ |